Glutamatergic tuning of hyperactive striatal projection neurons controls the motor response to dopamine replacement in parkinsonian primates
Dopamine (DA) loss in Parkinson's disease (PD) alters the function of striatal projection
neurons (SPNs) and causes motor deficits, but DA replacement can induce further
abnormalities. A key pathological change in animal models and patients is SPN
hyperactivity; however, the role of glutamate in altered DA responses remains elusive. We
tested the effect of locally applied AMPAR or NMDAR antagonists on glutamatergic
signaling in SPNs of parkinsonian primates. Following a reduction in basal hyperactivity by …
neurons (SPNs) and causes motor deficits, but DA replacement can induce further
abnormalities. A key pathological change in animal models and patients is SPN
hyperactivity; however, the role of glutamate in altered DA responses remains elusive. We
tested the effect of locally applied AMPAR or NMDAR antagonists on glutamatergic
signaling in SPNs of parkinsonian primates. Following a reduction in basal hyperactivity by …
Glutamatergic Tuning of Hyperactive Striatal Projection Neurons Controls the Motor Response to Dopamine Replacement in Parkinsonian Primates
A Scimemi, A Singh, MA Jenkins, KJ Burke Jr… - 2018 - scholarsarchive.library.albany.edu
Dopamine (DA) loss in Parkinson's disease (PD) alters the function of striatal projection
neurons (SPNs) and causes motor deficits, but DA replacement can induce further
abnormalities. A key pathological change in animal models and patients is SPN
hyperactivity; however, the role of glutamate in altered DA responses remains elusive. We
tested the effect of locally applied AMPAR or NMDAR antagonists on glutamatergic
signaling in SPNs of parkinsonian primates. Following a reduction in basal hyperactivity by …
neurons (SPNs) and causes motor deficits, but DA replacement can induce further
abnormalities. A key pathological change in animal models and patients is SPN
hyperactivity; however, the role of glutamate in altered DA responses remains elusive. We
tested the effect of locally applied AMPAR or NMDAR antagonists on glutamatergic
signaling in SPNs of parkinsonian primates. Following a reduction in basal hyperactivity by …